aromasil has been researched along with entinostat in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Cruickshank, S; Ismail-Khan, RR; Klein, PM; Lee, MJ; Lichinitser, M; Melichar, B; Miller, KD; Munster, PN; Trepel, JB; Yardley, DA | 1 |
| Chen, PH; Ho, CL; Huang, TC; Kang, YN; Lee, CH; Lin, C; Wu, YY | 1 |
| Brown-Glaberman, UA; Budd, GT; Burkard, ME; Connolly, RM; Faller, BA; Kaufman, PA; Lee, MJ; Levine, EG; Miller, KD; Onitilo, AA; Piekarz, RL; Royce, ME; Smith, KL; Sparano, JA; Thomas, A; Trepel, JB; Winn, JS; Wolff, AC; Zhao, F | 1 |
| Iwata, H; Kimura, R; Lee, MJ; Masuda, N; Nishimura, Y; Saji, S; Sawaki, M; Shimomura, A; Tamura, K; Trepel, J; Yasojima, H; Yuno, A | 1 |
| Goncalves, A; Mezni, E; Sabatier, R; Vicier, C | 1 |
| Aruga, T; Iwasa, T; Iwata, H; Kaneda, A; Kaneko, K; Kawabata, A; Kobayashi, K; Lee, MJ; Masuda, N; Nakamura, R; Nishimura, Y; Saji, S; Seike, T; Tamura, K; Tokunaga, E; Trepel, JB; Tsurutani, J; Yamamoto, Y; Yamashita, T; Yonemori, K; Yuno, A | 1 |
2 review(s) available for aromasil and entinostat
| Article | Year |
|---|---|
Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Fulvestrant; Humans; Neoplasm Grading; Network Meta-Analysis; Piperazines; Postmenopause; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2020 |
[Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021].
Topics: Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Female; Humans; Imidazoles; Immune Checkpoint Inhibitors; Letrozole; Leuprolide; Oxazepines; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2022 |
4 trial(s) available for aromasil and entinostat
| Article | Year |
|---|---|
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Pyridines; Receptors, Estrogen | 2013 |
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Breast Neoplasms, Male; Double-Blind Method; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; South Africa; Time Factors; United States | 2021 |
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
Topics: Acetylation; Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hypophosphatemia; Japan; Lymphocyte Activation; Middle Aged; Nausea; Platelet Count; Progression-Free Survival; Pyridines | 2021 |
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estrogen Receptor alpha; Female; Humans; Lysine; Neoplasm Recurrence, Local; Receptors, Estrogen | 2023 |
1 other study(ies) available for aromasil and entinostat
| Article | Year |
|---|---|
Entinostat plus exemestane has activity in ER+ advanced breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Disease-Free Survival; Female; Humans; Pyridines; Receptors, Estrogen | 2013 |